The ephrin A1-EphA2 system promotes cardiac stem cell migration after infarction
Polina Goichberg1, Yingnan Bai, Domenico D'Amario
1Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Insights
Ephrin A1 activates human cardiac stem cells (hCSCs), enhancing their migration to damaged heart tissue and promoting cardiac repair. This targeted cell therapy offers a promising strategy for treating heart failure.
Area of Science:
- Cardiovascular Biology
- Stem Cell Biology
- Regenerative Medicine
Background:
- Understanding human cardiac stem cell (hCSC) trafficking is crucial for developing therapies for heart failure.
- The role of cell guidance systems in hCSC migration to cardiac niches requires further elucidation.
Purpose of the Study:
- To investigate if the Eph receptor/ephrin ligand system regulates hCSC motility in immunosuppressed infarcted hearts.
- To determine the therapeutic potential of targeting this system for cardiac repair.
Main Methods:
- Cardiac niches and hCSCs were analyzed for ephrin A1 and EphA2 expression.
- hCSCs were treated with ephrin A1 in vitro and in vivo following myocardial infarction.
- Cellular responses, motility, cardiac regeneration, and functional recovery were assessed.
Main Results:
- Cardiomyocytes expressed ephrin A1, while hCSCs expressed EphA2.
- Ephrin A1 treatment induced hCSC motility and migration in vitro and in vivo.
- Animals treated with ephrin A1-activated hCSCs showed a 2-fold increase in regenerated myocardium, improved cardiac function, and reduced arrhythmias.
Conclusions:
- Ephrin A1 enhances the migration and cardiac repair capabilities of EphA2-positive hCSCs.
- Targeting hCSCs with ephrin A1 in situ or ex vivo presents a novel strategy for improving cell delivery to injured heart tissue and managing heart disease.
Rationale:
Understanding the mechanisms that regulate trafficking of human cardiac stem cells (hCSCs) may lead to development of new therapeutic approaches for the failing heart.
Objective:
We tested whether the motility of hCSCs in immunosuppressed infarcted animals is controlled by the guidance system that involves the interaction of Eph receptors with ephrin ligands.
Methods And Results:
Within the cardiac niches, cardiomyocytes expressed preferentially the ephrin A1 ligand, whereas hCSCs possessed the EphA2 receptor. Treatment of hCSCs with ephrin A1 resulted in the rapid internalization of the ephrin A1-EphA2 complex, posttranslational modifications of Src kinases, and morphological changes consistent with the acquisition of a motile cell phenotype. Ephrin A1 enhanced the motility of hCSCs in vitro, and their migration in vivo following acute myocardial infarction. At 2 weeks after infarction, the volume of the regenerated myocardium was 2-fold larger in animals injected with ephrin A1-activated hCSCs than in animals receiving control hCSCs; this difference was dictated by a greater number of newly formed cardiomyocytes and coronary vessels. The increased recovery in myocardial mass with ephrin A1-treated hCSCs was characterized by further restoration of cardiac function and by a reduction in arrhythmic events.
Conclusions:
Ephrin A1 promotes the motility of EphA2-positive hCSCs, facilitates their migration to the area of damage, and enhances cardiac repair. Thus, in situ stimulation of resident hCSCs with ephrin A1 or their ex vivo activation before myocardial delivery improves cell targeting to sites of injury, possibly providing a novel strategy for the management of the diseased heart.
Related Concept Videos
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
01:19Clinical Applications of Epidermal Stem Cells